Profilo
Tom Willis is currently a Director at SonoThera, Inc. He was previously a Director at Adaptive Biotechnologies Corp.
Posizioni attive di Tom Willis
Società | Posizione | Inizio |
---|---|---|
SonoThera, Inc.
SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Tom Willis
Società | Posizione | Fine |
---|---|---|
ADAPTIVE BIOTECHNOLOGIES CORPORATION | Direttore/Membro del Consiglio | 01/01/2019 |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
ADAPTIVE BIOTECHNOLOGIES CORPORATION | Health Technology |
Aziende private | 1 |
---|---|
SonoThera, Inc.
SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- Tom Willis